Italian position paper proposes a staged healthspan agenda for the national health service
This Italian position paper describes Italy's demographic and healthspan gap and its hospital-centric health service, then proposes five investment priorities for longevity medicine, which it frames as a staged agenda still to be evaluated. [1]
Automatic summary · not editorially reviewed
The key findings
Adults aged 65 and older are 24.1% of Italy's population, the highest share in the EU, with a projected median age of 51 years by 2050. [1]
Life expectancy at birth is 85.4 years for women and 81.4 for men, while Healthy Life Years are only 69.6 and 68.5. [1]
The paper proposes five investment priorities, including validated biomarkers of biological age and adaptive trials, as a staged agenda for evaluation. [1]
The source at a glance
- Study type / format
- Position paper (abstract only)
- Population / context
- Italy's general population, with figures on adults aged 65 and older and 75 and older.
- Summary based on
- Study abstract
- Original publication
- July 16, 2026
Italy's ageing population and lifespan-healthspan divide
The paper reports that adults aged 65 and older make up 24.1% of Italy's population, the highest share in the EU, with a projected median age of 51 years by 2050. Life expectancy at birth is 85.4 years for women and 81.4 for men, but Healthy Life Years are only 69.6 and 68.5, which the authors call a substantial lifespan-healthspan divide. Multimorbidity and disability exceed 60% in adults aged 75 and older, and women carry a disproportionate share as patients and as caregivers.
Supporting source [1]
Hospital-centric service and exploratory longevity tools
The authors describe the Italian National Health Service as hospital-centric, regionally fragmented and predominantly reactive, with prevention a historically modest share of total spending. They present longevity medicine as an emerging, prevention-oriented discipline aimed at extending healthspan, defined here as the portion of life lived in good health with preserved physical and cognitive function and without significant disability or multimorbidity. It combines multi-omic biomarkers, digital monitoring, adaptive trial methods and life-course risk stratification. Most of these tools remain exploratory or surrogate, and clinical utility has yet to be established.
Supporting source [1]
Five proposed priorities framed as a staged agenda
The position paper advocates multidisciplinary translational research and names five strategic investment priorities: clinically validated biomarkers of biological age; interoperable digital monitoring platforms; Bayesian adaptive multimodal trials; explainable artificial intelligence tools for risk stratification; and longevity-informed curricula in medical training. The authors state that these proposals should be regarded as a staged agenda for evaluation, and that their relevance will depend on whether they deliver measurable gains in patient-relevant outcomes, feasibility and cost-effectiveness within the service.
Supporting source [1]
How to interpret this
This is an abstract of a position paper; the full text was not reviewed. The paper presents proposals, not tested interventions, and the authors state that most longevity tools remain exploratory or surrogate and that clinical utility has yet to be established.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Marino N, Fiore M, Stingi A, Cipriano A, Chadha AS, Ricordi C, Della-Morte D, di Fagagna FD, Demaria M, Quarta M, Sebastiano V, Ferrucci L, Tasciotti E. · europepmc.org · July 16, 2026